A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects
A Phase I, Randomized, Single-Blinded, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of MOD-6031 in Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Tel Aviv, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male, between 18 to 55 years of age.
- BMI 27-35 Kg/m2 (inclusive).
- Generally good health.
- Triglyceride ≤ 400mg/ml
- ECG with no clinically significant abnormalities.
- Negative HIV, hepatitis B or hepatitis C serology tests at screening
- No significant abnormalities in clinical laboratory parameters
- No history of alcohol or drug abuse.
Exclusion Criteria:
- History of clinically significant medical condition.
- Any cardiac conduction defect.
- Any acute or unstable disease.
- History of malignancy diagnosed within the past 5 years.
- Known or suspected diabetes and/or HbA1C >6.4% on screening.
- Known allergy to any drug.
- Treatment with weight loss drugs (within 3 months prior to dosing).
- Liposuction or other surgery for weight loss within the last year.
- Evidence of eating disorders (bulimia, binge eating).
- History of regular alcohol consumption exceeding.
- Use of tobacco or nicotine-containing products.
- Subjects that have difficulty fasting or consuming the standard meals that will be provided.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose Cohort 1
20mg MOD-6031 / Placebo
|
|
|
Experimental: Dose Cohort 2
50mg MOD-6031 / Placebo
|
|
|
Experimental: Dose Cohort 3
100mg MOD-6031 / Placebo
|
|
|
Experimental: Dose Cohort 4
150mg MOD-6031 / Placebo
|
|
|
Experimental: Dose Cohort 5
200mg MOD-6031 / Placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Composite safety and tolerability parameters as measured by adverse events, electrocardiograms (ECG), laboratory results, vital signs and injection site reactions
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cmax of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)
Time Frame: 0 to 30 days
|
0 to 30 days
|
|
Tmax of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)
Time Frame: 0 to 30 days
|
0 to 30 days
|
|
AUC(0-t) of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)
Time Frame: 0 to 30 days
|
0 to 30 days
|
|
AUC(inf) of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)
Time Frame: 0 to 30 days
|
0 to 30 days
|
|
Elimination rate constant of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)
Time Frame: 0 to 30 days
|
0 to 30 days
|
|
T(½) of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)
Time Frame: 0 to 30 days
|
0 to 30 days
|
|
CL/F of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)
Time Frame: 0 to 30 days
|
0 to 30 days
|
|
Vz/F of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)
Time Frame: 0 to 30 days
|
0 to 30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CP-6-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.